Nanozyme-Enabled Treatment of Cardio- and Cerebrovascular Diseases

Small. 2023 Mar;19(13):e2204809. doi: 10.1002/smll.202204809. Epub 2022 Oct 3.

Abstract

Cardio- and cerebrovascular diseases are two major vascular-related diseases that lead to death worldwide. Reactive oxygen species (ROS) play a vital role in the occurrence and exacerbation of diseases. Excessive ROS induce cellular context damage and lead to tissue dysfunction. Nanozymes, as emerging enzyme mimics, offer a unique perspective for therapy through multifunctional activities, achieving essential results in the treatment of ROS-related cardio- and cerebrovascular diseases by directly scavenging excess ROS or regulating pathologically related molecules. This review first introduces nanozyme-enabled therapeutic mechanisms at the cellular level. Then, the therapies for several typical cardio- and cerebrovascular diseases with nanozymes are discussed, mainly including cardiovascular diseases, ischemia reperfusion injury, and neurological disorders. Finally, the challenges and outlooks for the application of nanozymes are also presented. This review will provide some instructive perspectives on nanozymes and promote the development of enzyme-mimicking strategies in cardio- and cerebrovascular disease therapy.

Keywords: cardio- and cerebrovascular diseases; nanomedicine; nanozymes; reactive oxygen species.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cardiovascular Diseases* / drug therapy
  • Cerebrovascular Disorders* / drug therapy
  • Humans
  • Reactive Oxygen Species

Substances

  • Reactive Oxygen Species